HomeInsightsStock Comparison

Pharmaids Pharmaceuticals Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Pharmaids Pharmaceuticals Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jul 19, 2025

Key Highlights

  • The Latest Trading Price of Pharmaids Pharmaceuticals Ltd is ₹ 68.07 as of 18 Jul 15:30.
  • The P/E Ratio of Pharmaids Pharmaceuticals Ltd is 89.4 as of March 2022 .The P/E Ratio of Senores Pharmaceuticals Ltd is 0 as of March 2022.
  • The Market Cap of Pharmaids Pharmaceuticals Ltd is ₹ 12.9 crore as of March 2022 .The Market Cap of Senores Pharmaceuticals Ltd is ₹ 0 crore as of March 2022.
  • The revenue of Pharmaids Pharmaceuticals Ltd for the Mar '25 is ₹ 4.9 crore as compare to the Sep '24 revenue of ₹ 5.25 crore. This represent the decline of -6.67% The revenue of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 125.98 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16%.
  • The ebitda of Pharmaids Pharmaceuticals Ltd for the Mar '25 is ₹ -3.77 crore as compare to the Sep '24 ebitda of ₹ -2.61 crore. This represent the growth of 44.44% The ebitda of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 31.21 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16%.
  • The net profit of Pharmaids Pharmaceuticals Ltd changed from ₹ -1.3 crore to ₹ -4.8 crore over 8 quarters. This represents a CAGR of 92.15% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 7.11 crore to ₹ 17.97 crore over 6 quarters. This represents a CAGR of 85.55% .
  • The Dividend Payout of Pharmaids Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Pharmaids Pharmaceuticals Ltd

  • Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana are the suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in the areas of Orthopedic, Neuro and Gastro etc.
  • The technical team uses quality proven chemical compounds and standard processing methods maintaining proper hygiene standards.
  • The Company is primarily engaged in business of manufacturing of Generics, Bulk Drugs in various forms like tablets, capsules, liquids and powders etc., in allopathic and herbal Ayurvedic and Natural drug formulation. Emergent Bio Naturals Limited (EBNL) was amalgamated with the Company in 2019-20 and the Scheme of Amalgamation was effective on September 27, 2019.
  • Pursuant to the Scheme, 69,05,734 Equity Shares were allotted to Shareholders of Emergent Bio Naturals Limited on November 27, 2019.

About Senores Pharmaceuticals Ltd

  • Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
  • Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
  • The Regulated Markets business is focused on Regulated Markets of US and Canada.
  • The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

Pharmaids Pharmaceuticals Ltd News Hub

News

Pharmaids Pharmaceuticals to discuss results

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

21 May 2025 13:01

News

Pharmaids Pharmaceuticals to table results

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

08 Feb 2025 15:39

News

Pharmaids Pharmaceuticals to announce Quarterly Result

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

08 Nov 2024 12:31

News

Pharmaids Pharmaceuticals AGM scheduled

Pharmaids Pharmaceuticals announced that the 35th Annual General Meeting (AGM) of the comp...

Read more

03 Sep 2024 17:10

News

Pharmaids Pharmaceuticals to convene board meeting

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

21 Aug 2024 10:05

News

Pharmaids Pharmaceuticals schedules board meeting

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

07 Aug 2024 13:55

Senores Pharmaceuticals Ltd News Hub

News

Senores Pharmaceuticals to discuss results

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23...

Read more

17 Jul 2025 16:11

News

Senores Pharmaceuticals to hold board meeting

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 15...

Read more

10 May 2025 11:12

News

Senores Pharmaceuticals Inc. to acquire USFDA approved ANDA for Tramadol Tablets

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

09 May 2025 09:29

News

Senores Pharmaceuticals gains on acquiring Topiramate tablets from Wockhardt

Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE. The market size of Topiramate t...

Read more

06 May 2025 10:51

News

Senores inks deal to acquire Wockhardt's ANDA for Topiramate

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

05 May 2025 18:55

News

Senores Pharmaceuticals to acquire 14 ANDAs from Dr Reddy's

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

04 Mar 2025 14:23

BlinkX Score for Pharmaids Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Pharmaids Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Pharmaids Pharmaceuticals Ltd or Senores Pharmaceuticals Ltd?

Market cap of Pharmaids Pharmaceuticals Ltd is 240 Cr while Market cap of Senores Pharmaceuticals Ltd is 2,876 Cr

What are the key factors driving the stock performance of Pharmaids Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Pharmaids Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Pharmaids Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd?

As of July 19, 2025, the Pharmaids Pharmaceuticals Ltd stock price is INR ₹68.07. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹624.6.

How do dividend payouts of Pharmaids Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Pharmaids Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions